

---

## ExpreS<sup>2</sup>ion's CEO in interview on achievements in 2020 and the company's outlook for 2021

**ExpreS<sup>2</sup>ion Biotech Holding AB ("ExpreS<sup>2</sup>ion") publishes an interview with the company's CEO Bent Frandsen, in which he sums up the company's achievements in 2021 and the outlook for the rest of 2021 and beyond. This includes discussing the status of the ABNCoV2 COVID-19 vaccine program and the recently in-licensed ES2B-C001 HER2 breast cancer vaccine project.**

The CEO interview is available via this link: <https://mailchi.mp/expres2ionbio.com/february2021>

### **Certified Adviser**

Svensk Kapitalmarknadsgranskning AB  
Telefon: +46 11 32 30 732  
E-post: [ca@skmg.se](mailto:ca@skmg.se)

### **For further information about ExpreS<sup>2</sup>ion Biotech Holding AB, please contact:**

Bent U. Frandsen, CEO  
Telephone: +45 4256 6869  
E-mail: [buf@expres2ionbio.com](mailto:buf@expres2ionbio.com)

---

### **About ExpreS<sup>2</sup>ion**

ExpreS<sup>2</sup>ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS<sup>2</sup>ion Biotech Holding AB with company register number 559033-3729. ExpreS<sup>2</sup>ion has developed a unique technology platform, ExpreS<sup>2</sup>, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS<sup>2</sup> is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS<sup>2</sup>ion develops novel capsid VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit [www.expres2ionbio.com](http://www.expres2ionbio.com) and [www.adaptvac.com](http://www.adaptvac.com).